Mirum pharmaceuticals, inc.MIRM.US Overview
US StockHealthcare
(No presentation for MIRM)
MIRM Overall Performance
MIRM AI Analysis & Strategy
MIRM Recent Performance
0.96%
Mirum pharmaceuticals, inc.
0.81%
Avg of Sector
-1.14%
S&P500
MIRM PowerScanner
MIRM Key Information
MIRM Valuation Metrics
MIRM Earnings Table
MIRM Profile
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.